Indianapolis, Ind., March 08, 2023 (GLOBE NEWSWIRE) -- #" Success As Unique As Our Kids™ Bierman Autism Centers
Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal 10-07-2024, 07:00